Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 14 Recurrence 2 Neoplasms, Plasma Cell 1 Lymphoma 1

Interventions

Cyclophosphamide 60 Vincristine 57 Doxorubicin 54 Rituximab 48 Prednisone 44 Etoposide 35 Radiotherapy 34 Cytarabine 26 Filgrastim 22 Methotrexate 21 Bleomycin 21 Dexamethasone 18 Peripheral Blood Stem Cell Transplantation 14 Carmustine 14 Vinblastine 13 Prednisolone 13 VAP-cyclo protocol 12 Melphalan 12 Mitoxantrone 11 Mercaptopurine 10 Leucovorin 10 Dacarbazine 9 Ifosfamide 8 Granulocyte Colony-Stimulating Factor 8 Procarbazine 7 Methylprednisolone 7 Lenalidomide 7 Gemcitabine 7 Daunorubicin 7 Cisplatin 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma × elotuzumab × Clear all

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡